FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
20 percent of patients treated with Breyanzi achieved a complete response
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
20 percent of patients treated with Breyanzi achieved a complete response
Only registered members have full access to PracticeUpdate content.